Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety.
Wendy BernhardKris BarretoAyman El-SayedCarolina GonzalezRaja Solomon ViswasDarien ToledoAngel CasacoJohn DeCoteauHumphrey FongeClarence Ronald GeyerPublished in: BMC cancer (2021)
Here, we show preclinical studies demonstrating that nimotuzumab conjugated to IRDye800CW is safe and does not exhibit toxicities commonly associated with EGFR targeting antibodies.